NAA30 and cancer: shRNA-mediated knockdown of NAA30 gene in GICs demonstrated that NatC may serve as a therapeutic target in these types of cancer, as intracranial transplantation of such NatC depleted cells resulted in prolonged animal survival compared to control mice transplanted with unmodified GICs [62].